Skip to main content
main-content

Latest contributions from John Wilding

Latest contributions from John Wilding

10-14-2020 | Type 2 diabetes | Editorial | Article

Tirzepatide: A new challenger for type 2 diabetes management?

What does the future hold for the novel agent tirzepatide, a GIP/GLP-1 co-agonist? John Wilding examines what we know so far.

10-07-2020 | EASD 2020 | Conference coverage | Article

EASD 2020: Editorial Board conference highlights

Listen to Sanjay Kalra, John Wilding and Lori Berard reflecting on their research highlights of this year’s virtual 56th EASD Annual Meeting (39:05).

06-24-2020 | ADA 2020 | Conference coverage | Article

ADA 2020 goes virtual! Editorial Board conference highlights

Listen to our Editorial Board reflecting on their ADA scientific highlights, and its novel virtual format (34:17).

05-06-2020 | Type 2 diabetes | Editorial | Article

Oral semaglutide: A technical triumph, with caveats

Diabetologist and Editorial Board member John Wilding gives his opinion on the latest addition to the GLP-1RA class, oral semaglutide.

09-24-2019 | Type 2 diabetes | Podcast | Article

How was it for you? The experts discuss EASD 2019

Our clinical advisors discuss their EASD 2019 highlights, including new treatment options for children and older adults with type 2 diabetes, the complexities surrounding hypoglycemia prevention, and the implications of the VERIFY trial.

04-16-2019 | Nephropathy | Video | Article

Diabetes expert commentary: The CREDENCE trial

In this video interview, diabetes specialist John Wilding discusses how the CREDENCE trial findings may impact the treatment of people with type 2 diabetes and chronic kidney disease (3:31).

03-06-2019 | Diet | Video | Article

Expert commentary: The 2-year DiRECT outcomes

John Wilding discusses the implications of the 2-year outcomes of the DiRECT trial, and the questions that remain unanswered (4:17).

03-01-2019 | Retinopathy | Video | Article

Diabetic retinopathy: Treatment

Ophthalmologist Philip Burgess joins Clinical Diabetologist John Wilding to discuss the treatment of sight-threatening retinopathy and maculopathy in people with diabetes (9:11).

03-01-2019 | Retinopathy | Video | Article

Diabetic retinopathy: Pathogenesis

Ophthalmologist Philip Burgess joins Clinical Diabetologist John Wilding to discuss the disease processes that lead to retinopathy in people with diabetes (9:11).

03-01-2019 | Retinopathy | Video | Article

Diabetic retinopathy: Screening

Ophthalmologist Philip Burgess joins Clinical Diabetologist John Wilding to discuss diabetic retinopathy screening and the key role that it plays in reducing vision loss among people with diabetes (10:00).

12-14-2018 | Sleep apnea | Editorial | Article

Diabetes and obstructive sleep apnea syndrome: Double trouble

Obstructive sleep apnea syndrome is a common and potentially serious comorbidity in people with diabetes and obesity. John Wilding highlights what you need to know about the condition.

11-16-2018 | Dapagliflozin | Video | Article

Researcher comment: DECLARE-TIMI 58

DECLARE-TIMI 58 steering committee member John Wilding talks us through the trial's findings (5:49).

10-06-2018 | Albiglutide | EASD 2018 | Article

Expert commentary: The HARMONY trial

John Wilding discusses the unexpected results of HARMONY, the albiglutide cardiovascular outcomes study (2:43).

06-27-2018 | SGLT2 inhibitors | ADA 2018 | Article

Expert commentary: SGLT2 inhibition in type 1 diabetes patients

John Wilding has been sitting on the fence about the prospects for SGLT2 inhibitors in type 1 diabetes. Is he swayed by the latest findings? (3:43)

03-19-2018 | Diet | Podcast | Article

UK nutrition guidelines: A fresh approach

Board members John Wilding and Pamela Dyson talk about the fresh approach taken to the latest update of the Diabetes UK nutrition guidelines (9:43).

03-16-2018 | Obesity | Editorial | Article

The updated Diabetes UK nutrition guidelines: an obesity specialist’s view

John Wilding explains how the latest update of the nutrition guidelines will help clinicians working with patients with obesity (1:53).

02-13-2018 | Older adults | Editorial | Article

Does setting treatment targets risk the overtreatment of type 2 diabetes in older patients?

The drive to achieve lower HbA1c targets in older patients is not without concern or risk. Our UK Board address concerns highlighted by recent trials and discuss whether current guidelines do enough to mitigate the risks of overtreatment.

01-16-2018 | Type 1 diabetes | Editorial | Article

Sodium-glucose cotransporter-2 inhibitors for type 1 diabetes: Ready for prime time?

Editorial board member John Wilding casts a critical eye over the positive buzz surrounding the potential uses of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes treatment.

01-03-2018 | Physical activity | Editorial | Article

Physical activity for health, weight loss, and diabetes prevention and treatment: What should be recommended?

Editorial Board member John Wilding highlights the current evidence for the benefits of physical activity across various domains of type 2 diabetes care and prevention, presenting his view of what should be recommended.

11-28-2017 | Type 2 diabetes | Editorial | Article

Real-world evidence: Complementing clinical trials in type 2 diabetes

Editorial Board member John Wilding examines what real-world data means to today’s clinicians and presents his vision for the future of this type of evidence.

Image Credits